Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | “DNA Methyltransferase Inhibitors -Pipeline Insights, 2015” – A DelveInsight’s ReportDelveInsight, the leading market research and consulting company has added a new report “DNA Methyltransferase Inhibitors -Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on MOA Pipeline in
By: DelveInsight Business Research · The report gives information of 11+ pipeline drugs with 10+ companies actively involved in drug development. There is 1 drug in phase III, 1 in phase II, 2 in phase I, 4 in pre-clinical and 3 in discovery. · Astex Pharmaceuticals developing a lead product Guadecitabine whichis in Phase III. · R& · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, DNA Methyltransferase Inhibitors -Pipeline Insights, 2015 report provides the in-depth analysis of the pipeline assets across the DNA Methyltransferase Inhibitors. Therefore the report on DNA Methyltransferase Inhibitors -Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|